Clinical trials: Prolactinoma
Prolactinoma, Macroprolactinoma
How Estrogen Fluctuations Before Diagnosis Affect the Size Prolactin-secreting Tumors
Prolactinomas are the most common pituitary adenomas, representing about two-thirds of clinically relevant cases. Their prevalence is around 50 per 100,000 individuals, with an incidence of 3-5 new cases per 100,000 per year and…
- Trial name
- OEMacroPrL (NCT07268183)
- Testing
- Standardized questionnaire
- Where
- France
- Volunteers
- 171 people
- Sponsor
- Hospices Civils de Lyon
Panhypopituitarism, Gigantism/Acromegaly
An Investigation of Pituitary Tumors and Related Hypothalmic Disorders
There is a variety of tumors affecting the pituitary gland in childhood; some of these tumors (eg craniopharyngioma) are included among the most common central nervous system tumors in childhood.
- Conditions
- Panhypopituitarism, Gigantism/Acromegaly, Prolactinoma, Cushing Disease
- Trial name
- NCT00001595
- Testing
- Tissue specimen collection, MRI
- Where
- United States
- Volunteers
- 2,000 people, healthy volunteers welcome
- Sponsor
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Pituitary Diseases, Pituitary Neoplasms
Long Term Outcome Study in Patients With Pituitary Disorders
To determine the outcomes of patients with different pituitary disorders whether they are managed medically, surgically or expectantly.
- Trial name
- NCT03665064
- Volunteers
- 1,500 people
- Sponsor
- University of Alberta
Prolactinoma, Prolactin Excess
Safety and Potency of a High Cabergoline Dosage in Microprolactinomas
This will be a multicenter, prospective, randomized, open-label trial with women harboring microprolactinomas and treatment naïve.
- Trial name
- SPARAGMOS (NCT07463235)
- Testing
- Cabergoline
- Where
- 16 sites in Brazil
- Volunteers
- 70 people
- Sponsor
- University of Sao Paulo General Hospital
Prolactinoma, Pituitary Tumor
The PROMISE Survey
The PROMISE Survey was developed to systematically assess the real-world experiences, treatment preferences, side effects, and outcomes from both patients and physicians dealing with prolactinomas.
- Trial name
- NCT06936813
- Where
- Switzerland
- Volunteers
- 530 people
- Sponsor
- University Hospital, Basel, Switzerland
Prolactinoma, Prolactin-Producing Pituitary Tumor
Validation of a Quality of Life Metric "Prolac-10"
This is a short-term validation study of a quality of life metric "Prolac-10" for patients diagnosed with a prolactinoma, undergoing new medical therapy.
- Conditions
- Prolactinoma, Prolactin-Producing Pituitary Tumor, Pituitary Tumor, Prolactinoma Macroadenoma
- Trial name
- Prolac-10 (NCT04106531)
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Ohio State University
Prolactinoma
Metabolic Outcomes in Patients With Prolactinomas Under Dopamine Agonist Treatment
This randomized, active-controlled, parallel-arm, single-blind trial is to compare the effects of Dopamine agonists (DA) therapy targeting different established treatment strategies on glucose metabolism assessed by an oral…
- Trial name
- ProBOLIC (NCT07045935)
- Testing
- Cabergoline (Dopamine Agonist)
- Where
- Switzerland
- Volunteers
- 60 people
- Sponsor
- University Hospital, Basel, Switzerland
Hyperprolactinemia, Prolactinoma
Treatment of Hyperprolactinemia With the Non-ergoline Dopamine Agonist Ropinirole
The purpose of this study is to evaluate the use of the non-ergoline dopamine agonist ropinirole for the treatment of hyperprolactinemia in patients with idiopathic hyperprolactinemia and prolactinomas.
- Trial name
- NCT03038308
- Testing
- Ropinirole
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- Columbia University
Prolactinoma
Exercise Capacity and Physical Activity Level in Prolactinoma Patients
Prolactinoma, one of the most common pituitary adenomas, is an adenoma that causes excessive prolactin (PRL) secretion. An increase in prolactin level can cause weakness, decrease in muscle mass and fatigue.
- Trial name
- NCT05236829
- Where
- Turkey (Türkiye)
- Volunteers
- 38 people, healthy volunteers welcome
- Sponsor
- Hacettepe University
Brain and Central Nervous System Tumors
Temozolomide in Treating Patients With Invasive Pituitary Tumors
RATIONALE: Drugs used in chemotherapy, such as temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00601289
- Testing
- temozolomide, DNA methylation analysis, microarray analysis
- Sponsor
- Jonsson Comprehensive Cancer Center
Prolactinoma, Prolactin-Producing Pituitary Tumor
PRolaCT - Three Prolactinoma RCTs
This study aims to investigate if endoscopic trans-sphenoidal prolactinoma resection as a first line treatment, or as an equally valid second line treatment after a short (4-6 months) or long (>2 years) period of pretreatment…
- Trial name
- NCT04107480
- Testing
- Endoscopic trans-sphenoidal adenoma resection, Dopamine Agonists
- Where
- 3 sites in Netherlands
- Volunteers
- 880 people
- Sponsor
- Leiden University Medical Center
Pituitary Adenoma, Prolactinoma
Comparison of Treatment Outcome of Cabergoline According to Target Prolactin Levels in Patients With Prolactinoma
The aim of this study is to investigate whether inhibition of serum prolactin levels below normal range during cabergoline administration may reduce the recurrence rate after drug withdrawal in patients with prolactinomas.
- Conditions
- Pituitary Adenoma, Prolactinoma, Pituitary Tumor, Recurrence Tumor
- Trial name
- NCT03457389
- Testing
- Cabergoline
- Where
- South Korea
- Volunteers
- 68 people
- Sponsor
- Seoul National University Hospital
Pituitary Disease, Pituitary Incidentaloma
Seoul National University Pituitary Disease Cohort Study
The purpose of this study is to investigate the treatment and natural history of pituitary disease. We have a longstanding interest in pituitary disease including acromegaly, central diabetes insipidus, and nonfunctioning…
- Conditions
- Pituitary Disease, Pituitary Incidentaloma, Acromegaly, Central Diabetes Insipidus
- Trial name
- SNU-PIT (NCT03474601)
- Testing
- Dynamic hormone study and Magnetic resonance imaging
- Where
- South Korea
- Volunteers
- 1,600 people
- Sponsor
- Seoul National University Hospital
Pituitary Adenomas, Prolactinomas
Targeted Therapy With Lapatinib in Patients With Recurrent Pituitary Tumors Resistant to Standard Therapy
This study focuses on new therapies for a challenging disease in pituitary medicine, that of aggressive pituitary tumors which have limited therapeutic options beyond standard surgical, radiotherapy, and select medical therapies…
- Trial name
- NCT00939523
- Testing
- Lapatinib
- Where
- 3 sites in United States
- Volunteers
- 9 people
- Sponsor
- Cedars-Sinai Medical Center
Prolactinoma
Dopamine D2 Receptors(D2R) Imaging in Prolactinomas
To study the in vivo expression of dopamine D2 receptors in prolactinoma and the predictive role of dopamine D2 receptors PET-MR imaging in the therapeutic effect of dopamine agonists.
- Trial name
- NCT03717454
- Testing
- Surgery, Drug treatment
- Volunteers
- 50 people
- Sponsor
- Zhebao Wu
Resistance, Disease, Prolactinoma
Cabergoline Combined Hydroxychloroquine/Chloroquine to Treat Resistant Prolactinomas
The purpose of this study is to preliminarily evaluate the safety and efficacy of cabergoline combined hydroxychloroquine/chloroquine(HCQ/CQ) therapy for cabergoline-Resistant Prolactinomas
- Trial name
- NCT03400865
- Testing
- HCQ/CQ and CAB combined treatment
- Where
- 9 sites in China
- Volunteers
- 30 people
- Sponsor
- Zhebao Wu
Pituitary Neoplasm, Pituitary Adenoma
Rhinological Outcomes in Endonasal Pituitary Surgery
This is a prospective, multi-center observational study designed to address patient-reported nasal outcomes in adults undergoing endoscopic and microscopic surgical removal of pituitary tumors.
- Conditions
- Pituitary Neoplasm, Pituitary Adenoma, Prolactinoma, Cushings Disease
- Trial name
- NCT01504399
- Where
- 4 sites in United States
- Volunteers
- 235 people
- Sponsor
- St. Joseph's Hospital and Medical Center, Phoenix
Prolactinoma
Study on Therapy of Non-invasive Prolactinoma
the study aim to investigate the endocrine remission rate of non-invasive prolactinoma between transsphenoidal surgery treatment and Dopamine agonist treatment.
- Trial name
- TNAPA (NCT03353025)
- Testing
- transsphenoidal surgery treatment, dopamine agonist treatment
- Where
- China
- Volunteers
- 394 people
- Sponsor
- First Affiliated Hospital, Sun Yat-Sen University
Invasive Prolactinomas Involving the Cavernous Sinus
Dopamine Agonists Withdrawal Study of Invasive Prolactinomas Involving the Cavernous Sinus
The purpose of this study is to observe whether dopamine agonists can be safely withdrawn after the tumor volume and prolactin level of invasive prolactinomas involving the cavernous sinus have been effectively controlled through…
- Trial name
- NCT02536261
- Where
- 8 sites in China
- Volunteers
- 30 people
- Sponsor
- Zhebao Wu
Non-functioning Pituitary Adenomas, Prolactinomas
Response to Cabergoline and Pasireotide in Non-functioning Pituitary Adenomas and Resistant Prolactinomas
There are no available medical treatment options for patients with non-functioning pituitary adenomas (NFPA) or with resistant prolactinomas to dopamine agonists (DA) who are not cured by surgery.
- Trial name
- NCT01620138
- Testing
- Pasireotide, cabergoline
- Where
- Brazil
- Volunteers
- 21 people
- Sponsor
- Universidade Federal do Rio de Janeiro